New drug watch: ADZYNMA under surveillance for rare blood disorder
NCT ID NCT06441578
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 28 times
Summary
This study tracks side effects of ADZYNMA (recombinant ADAMTS13) in 40 people with congenital thrombotic thrombocytopenic purpura (cTTP), a rare blood clotting disorder. Participants receive the drug as part of their regular care, and doctors monitor them for 18 months. The goal is to see if the drug is safe and helps control the disease, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Japan
Conditions
Explore the condition pages connected to this study.